Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of six different antipsychotic medications, each with distinct mechanisms of action and side effect profiles. Aripiprazole is an atypical antipsychotic that acts as a partial agonist at dopamine D2 receptors. Chlorpromazine is a first-generation (typical) antipsychotic. Haloperidol is a high-potency first-generation antipsychotic with strong D2 receptor antagonism. Olanzapine is a second-generation (atypical) antipsychotic. Quetiapine is an atypical antipsychotic. Risperidone is an atypical antipsychotic available in long-acting injectable form. Using all six medications simultaneously would be highly unusual in clinical practice, though combinations of two antipsychotics are sometimes used in treatment-resistant cases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aripiprazole + chlorpromazine + haloperidol + olanzapine + quetiapine + risperidone.